文献速递心力衰竭与心肌病高血压

抑制新型DKK1-LRP5/6轴可预防糖尿病心肌病

Inhibition of a novel Dickkopf-1-LDL receptor-related proteins 5 and 6 axis prevents diabetic cardiomyopathy in mice.
PubMed 文献 · Eur Heart J · 2024-01-01

研究在人和糖尿病小鼠中探讨血清DKK1及DKK1-LRP5/6信号在糖尿病损伤中的作用,发现血压升高与血清DKK1升高正相关,LRP5/6与AT1R存在物理和功能互作。重组DKK1或条件性敲除LRP5/6导致AT1R激活、高血压及β-arrestin1激活和心脏损伤,而抗DKK1中和抗体可有效预防小鼠糖尿病心脏损伤。

要点

  • 血清DKK1升高与人类血压升高正相关。
  • LRP5/6缺失通过激活AT1R和β-arrestin1导致高血压和心脏损伤。
  • 抗DKK1中和抗体可预防小鼠糖尿病心脏损伤。

核心结论

  • 研究确立DKK1-LRP5/6-GPCR通路诱导糖尿病损伤,可能解释血DKK1升高的有害效应。
  • 监测和治疗性清除血DKK1可能是减轻糖尿病损伤的有前景策略。

研究设计与样本

  • 在人和糖尿病小鼠中研究血清DKK1及DKK1-LRP5/6信号在糖尿病损伤中的作用。

主要发现

  • 人类血压升高与血清DKK1升高正相关。
  • LRP5/6与AT1R存在物理和功能互作。
  • 注射重组DKK1蛋白或条件性敲除LRP5/6导致膜LRP5/6丢失,引起AT1R激活、高血压、β-arrestin1激活和心脏损伤。
  • 与常用抗高血压药不同,给予抗DKK1中和抗体有效预防小鼠糖尿病心脏损伤。

临床怎么用

  • 监测血DKK1可能有助于评估糖尿病高血压患者的心脏损伤风险。
  • 治疗性清除血DKK1或使用抗DKK1中和抗体可能成为减轻糖尿病损伤的策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Anti-hypertensive agents are one of the most frequently used drugs worldwide. However, no blood pressure-lowering strategy is superior to placebo with respect to survival in diabetic hypertensive patients. Previous findings show that Wnt co-receptors LDL receptor-related proteins 5 and 6 (LRP5/6) can directly bind to several G protein-coupled receptors (GPCRs). Because angiotensin II type 1 receptor (AT1R) is the most important GPCR in regulating hypertension, this study examines the possible mechanistic association between LRP5/6 and their binding protein Dickkopf-1 (DKK1) and activation of the AT1R and further hypothesizes that the LRP5/6-GPCR interaction may affect hypertension and potentiate cardiac impairment in the setting of diabetes. METHODS: The roles of serum DKK1 and DKK1-LRP5/6 signalling in diabetic injuries were investigated in human and diabetic mice. RESULTS: Blood pressure up-regulation positively correlated with serum DKK1 elevations in humans. Notably, LRP5/6 physically and functionally interacted with AT1R. The loss of membrane LRP5/6 caused by injection of a recombinant DKK1 protein or conditional LRP5/6 deletions resulted in AT1R activation and hypertension, as well as β-arrestin1 activation and cardiac impairment, possibly because of multiple GPCR alterations. Importantly, unlike commonly used anti-hypertensive agents, administration of the anti-DKK1 neutralizing antibody effectively prevented diabetic cardiac impairment in mice. CONCLUSIONS: These findings establish a novel DKK1-LRP5/6-GPCR pathway in inducing diabetic injuries and may resolve the long-standing conundrum as to why elevated blood DKK1 has deleterious effects. Thus, monitoring and therapeutic elimination of blood DKK1 may be a promising strategy to attenuate diabetic injuries.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Ma E, Wo D, Chen J, et al. Inhibition of a novel Dickkopf-1-LDL receptor-related proteins 5 and 6 axis prevents diabetic cardiomyopathy in mice. Eur Heart J. 2024. PMID: 38152853. doi:10.1093/eurheartj/ehad842

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。